Overview

Phase IIb Randomised Trial of ATRA in a Novel Drug Combination for Pancreatic Cancer

Status:
Not yet recruiting
Trial end date:
2024-05-29
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-centre, randomised, stratified, phase IIb clinical trial of ATRA administered in combination with gemcitabine and nab-paclitaxel in patients with laPDAC.
Phase:
Phase 2
Details
Lead Sponsor:
Queen Mary University of London
Collaborators:
Celgene
Medical Research Council
Treatments:
Albumin-Bound Paclitaxel
Gemcitabine
Paclitaxel
Tretinoin